Catalent Buys Facilities in US and Italy

02:53 EDT 8 Jul 2019 | CHEManager

Catalent Biologics, through its Paragon Gene Therapy business, has agreed to assume the leases to two Novavax facilities in Maryland, USA. The move, said Novavax, will reduce its operating costs and provide a cash payment of about $18 million, allowing the company to focus on advancing its NanoFlu and ResVax vaccines through the next phases of clinical development and regulatory review.

Original Article: Catalent Buys Facilities in US and Italy


More From BioPortfolio on "Catalent Buys Facilities in US and Italy"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...